Projected to surpass $38 billion in value by 2032, artificial intelligence (AI) simulations—particularly digital twins—are reshaping the healthcare landscape. These virtual replicas of individuals possess an uncanny ability to replicate human biological complexities, making them powerful tools for patient care…
Laser Photonics Corporation a global leader in the development of industrial laser systems for material processing applications, has announced the launch of a new research and development (R&D) initiative aimed at advancing laser solutions for pharmaceutical tablet drilling, wafer scribing,…
Altasciences, a full-service early-phase contract research organization, is proud to have partnered with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing next-generation therapies for obesity and metabolic diseases. This collaboration has been pivotal in supporting the development of innovative…
Genentech, part of the Roche Group, has provided an update on the Phase III SKYSCRAPER-01 study, which evaluated the combination of tiragolumab with Tecentriq® (atezolizumab) compared to Tecentriq alone in patients with PD-L1-high, locally advanced or metastatic non-small cell lung…
Menarini Presents Data at SABCS 2024 Showcasing ORSERDU®’s Potential in ER+/HER2- Metastatic Breast Cancer The Menarini Group and its subsidiary, Stemline Therapeutics, are set to unveil new and expanded findings on ORSERDU® (elacestrant) at the 2024 San Antonio Breast Cancer…
Exact Sciences Highlights the Impact of Oncotype DX® and Genomic Insights at SABCS 2024 Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, will present a robust array of new data at the 2024 San Antonio Breast Cancer Symposium®…
Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, has announced the integration of its advanced AI solutions into routine clinical practice at Institut Curie, one of the world’s most renowned cancer centers. Pathologists at Institut Curie are now…
Eli Lilly and Company (NYSE: LLY) has revealed encouraging Phase 2 results for muvalaplin, an investigational once-daily oral inhibitor targeting lipoprotein(a) [Lp(a)], a hereditary risk factor for cardiovascular disease. The trial demonstrated that muvalaplin significantly lowered elevated Lp(a) levels, achieving…
Ipsen (Euronext: IPN; ADR: IPSEY) presented new data at the American Association for the Study of Liver Diseases (AASLD) from two Phase III open-label extension studies, evaluating the long-term efficacy and safety of Bylvay® in patients with Progressive Familial Intrahepatic…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has provided an update regarding its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) for €11.00 per share in cash, valuing the transaction at approximately €2.0 billion. A presentation on Halozyme’s investor relations website outlines…
Brenus Pharma has announced the publication of a scientific article in Frontiers in Oncology detailing the results of its novel “off-the-shelf” cancer treatment. The company’s innovative platform replicates patients’ relapsing conditions in the lab to train the immune system to…
Care Access, a global clinical research company focused on advancing medicine, is hosting a Heart & Kidney Health Screening event in Houston, Texas. The initiative is designed to raise awareness about health risks, including lipoprotein(a) [Lp(a)], a harmful type of…